Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label Phase 3 study of subcutaneous efgartigimod PH20 in generalized myasthenia gravis
2020-004086-38Phase 3Completed
- Sponsor
- argenx
- Start
- Feb 2021
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of efgartigimod alfa in myasthenia gravis (MG), sponsored by argenx. Primary endpoint: Incidence of Serious Adverse Events and Adverse Events of Special Interest. Started Feb 2021; status: completed.
02
Drugs
efgartigimod alfa
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on 2020-004086-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-004086-38.